INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Open-market saleVerified data

Hohenleitner Susan sold ARDX

Chief Financial Officer · ARDELYX, INC. · Common Stock

Side
SELL
Value
$6,009
Shares
1,558
Price
$3.86
Executed
Aug 21, 2026
Disclosed
Aug 25, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 21 executedAug 25, 2026 disclosed

ARDX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
32/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $6K reported value · 0.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering+15 / 15

    5 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ARDX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    32
    FD
    Foster Eric DuaneChief Commercial Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$9,932
    2,575 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    39
    BP
    Brady James ParkerChief Human Resources Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$51K
    13.2K sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    BP
    Brady James ParkerChief Human Resources Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$7,621
    1,976 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    KM
    Kelliher MikeChief Business Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$7,722
    2,002 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$6,688
    1,734 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$13K
    3,486 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$12K
    3,089 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    RJ
    Reilly Joseph JamesSee Remarks
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$4,281
    1,110 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    FD
    Foster Eric DuaneChief Commercial Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$10K
    2,598 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    KM
    Kelliher MikeChief Business Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$12K
    3,104 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    KM
    Kelliher MikeChief Business Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$10K
    2,652 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    RJ
    Reilly Joseph JamesSee Remarks
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$11K
    2,872 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$9,372
    2,430 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    32
    FD
    Foster Eric DuaneChief Commercial Officer
    ARDXARDELYX, INC.
    Open-market sale
    		SELL$13K
    3,389 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    0
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Option exercise · 10b5-1 plan
    		M$31K
    31.0K sh
    		Jun 18, 2026Jun 22, 2026
    traded Jun 18, 2026
    		+4dSEC FORM 4

    Evidence

    0
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Option exercise · 10b5-1 plan
    		M—
    31.0K sh
    		Jun 18, 2026Jun 22, 2026
    traded Jun 18, 2026
    		+4dSEC FORM 4

    Evidence

    11
    WA
    Williams Laura AChief Patient Officer
    ARDXARDELYX, INC.
    Open-market sale · 10b5-1 plan
    		SELL$490K
    81.9K sh
    		Jun 18, 2026Jun 22, 2026
    traded Jun 18, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CO
    Cadoret-Manier OnaizaDirector
    ARDXARDELYX, INC.
    Grant or award
    		A—
    26.5K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    13
    BM
    Bhanji MunaDirector
    ARDXARDELYX, INC.
    Grant or award
    		A—
    26.5K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BM
    Bhanji MunaDirector
    ARDXARDELYX, INC.
    Grant or award
    		A—
    39.7K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002093095-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 21, 2026
    Published
    Aug 25, 2026
    Ingested by INSIDER
    Nov 5, 02:21 UTC
    Last re-read
    Nov 5, 02:21 UTC

    Extracted facts

    Filer
    Hohenleitner Susan
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    ARDELYX, INC.
    Ticker
    ARDX
    Shares
    1,558
    Price per share
    $3.86
    Value
    $6,009
    Execution date (reported)
    Aug 21, 2026
    Owned after transaction
    227.5K shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 1,558
    • Price: $3.8569

    = $6,009

    What this establishes

    Hohenleitner Susan filed this Form 4 reporting a open-market sale of ARDX on Aug 21, 2026. It became public on Aug 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Hohenleitner Susancik:0002093095
    Issuer
    ARDELYX, INC.cik:0001437402

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.